Holen Sie sich die Stockscreener-App
0.85
2.30%
-0.02
Schlusskurs vom Vortag:
$0.87
Offen:
$0.809
24-Stunden-Volumen:
64,115
Relative Volume:
0.04
Marktkapitalisierung:
$3.03M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.35M
KGV:
-2.2368
EPS:
-0.38
Netto-Cashflow:
$-5.48M
1W Leistung:
-5.35%
1M Leistung:
-32.00%
6M Leistung:
+104.87%
1J Leistung:
+71.72%
1-Tages-Spanne:
$0.809
$0.8532
1-Wochen-Bereich:
$0.809
$0.918
52-Wochen-Spanne:
$0.2872
$3.30
Shuttle Pharmaceuticals Holdings Inc Stock (SHPH) Company Profile
Firmenname
Shuttle Pharmaceuticals Holdings Inc
Sektor
Telefon
(240) 403-4212
Adresse
401 PROFESSIONAL DRIVE, GAITHERSBURG
Vergleichen Sie SHPH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SHPH
Shuttle Pharmaceuticals Holdings Inc
|
0.85 | 3.03M | 0 | -7.35M | -5.48M | -0.38 |
|
ZTS
Zoetis Inc
|
176.74 | 80.59B | 9.15B | 2.43B | 2.31B | 4.92 |
|
HLN
Haleon Plc Adr
|
9.72 | 44.17B | 14.26B | 1.55B | 0 | 0.3327 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.57 | 42.61B | 30.27B | 1.93B | 3.45B | 0.444 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.57 | 18.77B | 16.77B | -959.00M | 1.37B | -2.00 |
|
VTRS
Viatris Inc
|
13.22 | 15.73B | 15.05B | -883.30M | 1.89B | 1.53 |
Shuttle Pharmaceuticals Holdings Inc Aktie (SHPH) Neueste Nachrichten
Shuttle Pharma Expands Patient Enrollment for Phase 2 - GlobeNewswire
Shuttle Pharmaceuticals stock hits 52-week low at $0.83 By Investing.com - Investing.com UK
Shuttle Pharmaceuticals Starts Phase 2 Trial for Glioblastoma - TipRanks
Shuttle Pharmaceuticals Launches Phase 2 Trial for Breakthrough Glioblastoma Treatment | SHPH Stock News - StockTitan
Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Up - GuruFocus.com
Micro Cap Company Is Soaring On Phase 2 Trial Update - MSN
500: Something went wrong - Investing.com UK
Shuttle Pharma Provides Third Quarter 2024 Corporate Update - GlobeNewswire
Shuttle Pharma Advances Phase 2 Trial, Secures $4.5M Funding for Cancer Treatment Study | SHPH Stock News - StockTitan
Shuttle Pharmaceuticals’ $4.5 Million Common Stock Offering - Global Legal Chronicle
Top 3 Penny Stocks to Watch Today – October 31, 2024 - The Global Domains News
Shuttle Pharma (SHPH) Stock Surges on Clinical Trial, Financing and Debt Elimination News - MSN
Shuttle Pharma Raises $4.5M for Clinical Trials - TipRanks
3 Penny Stocks to Watch Now, 10/31/24 - TipRanks
Shuttle Pharmaceuticals Successfully Doses First Patients in Phase 2 Clinical Trial for Glioblastoma Treatment - Defense World
Shuttle Pharma doses three subjects in Phase II glioblastoma treatment trial - Yahoo! Voices
"Stocks Key Trendlines: PRSO, PFIE, SHPH, BKYI, LIXT on the Verge of Breakthroughs" - Marketscreener.com
SHPHShuttle Pharmaceuticals Holdings, Inc. Latest Stock News & Market Updates - StockTitan
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of - GlobeNewswire
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - StockTitan
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - Benzinga
Shuttle Pharma Pays Off Senior Secured Convertible Note - GlobeNewswire
Micro Cap Soaring On Phase 2 Trial Update - Invezz
TSX American Preferred Stock Index (STNC) QuotePress Release - The Globe and Mail
US Stocks Mixed; McDonald's Posts Upbeat Earnings - Benzinga
Shuttle Pharmaceuticals Advances Phase 2 Glioblastoma Trial - TipRanks
Shuttle Pharma (SHPH) Stock Rises Pre-Market With Completion Site Enrollments - Stocks Telegraph
Shuttle Pharma Doses First Patients in Phase 2 Clinical - GlobeNewswire
Shuttle Pharma Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma - Yahoo Finance
Why VF Corp Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket - Benzinga
Shuttle Pharmaceuticals Shares Rise 63% on Drug-Study Site Update - MarketWatch
Shuttle Pharmaceuticals Advances Glioblastoma Clinical Trials - TipRanks
Shuttle Pharma Completes Clinical Trial Site Enrollment for - GlobeNewswire
Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma - Marketscreener.com
Shuttle Pharmaceuticals to Present at ThinkEquity Conference - TipRanks
Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024 - GlobeNewswire
Shuttle Pharmaceuticals completes funding round, raises $790,000 By Investing.com - Investing.com Canada
Shuttle Pharmaceuticals completes funding round, raises $790,000 - Investing.com India
Shuttle Pharmaceuticals Holdings, Inc. announced that it expects to receive $1.3 million in funding - Marketscreener.com
Kingsoft Cloud Holdings Limited (NASDAQ:KC) Short Interest Update - Defense World
Office Properties Income Trust (NASDAQ:OPINL) Shares Up 3.9% – Here’s Why - Defense World
Munters Group AB (publ) (OTCMKTS:MMNNF) Stock Price Down 14.1% – Should You Sell? - Defense World
Shuttle Pharmaceuticals (NASDAQ:SHPH) Shares Up 7.2% – Should You Buy? - Defense World
Getlink: Shuttle Traffic in September 2024 - Yahoo Finance
SHPH stock touches 52-week low at $1.11 amid market challenges - Investing.com Australia
SHPH stock touches 52-week low at $1.11 amid market challenges By Investing.com - Investing.com South Africa
Stock Market Today: S&P 500 rides Nvidia-led tech surge to close higher - Investing.com
Union Pacific says FXE issuing some US-Mexico grain shuttle permits - Yahoo Finance
American Century Companies Inc. Lowers Stock Holdings in Paycom Software, Inc. (NYSE:PAYC) - Defense World
Ensign Peak Advisors Inc Sells 13,160 Shares of Owens Corning (NYSE:OC) - Defense World
Frank Rimerman Advisors LLC Takes $386,000 Position in Texas Roadhouse, Inc. (NASDAQ:TXRH) - Defense World
Finanzdaten der Shuttle Pharmaceuticals Holdings Inc-Aktie (SHPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.83%
1.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):